Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HIV-1 gp41 N-terminal heptad repeat (NHR) hydrophobic pocket is a highly conserved structural domain within the transmembrane subunit of the HIV-1 envelope glycoprotein (gp41). It plays a pivotal role during the fusion of the viral envelope with the host cell membrane, a process triggered by the binding of gp120 to CD4 and coreceptors (Chan et al., 1997). Upon activation, gp41 transitions into a pre-hairpin intermediate where three NHR segments form a central trimeric coiled-coil, creating a deep hydrophobic groove or pocket. This pocket serves as a critical docking site for the C-terminal heptad repeat (CHR) region; their interaction forms a stable six-helix bundle (6HB) that drives membrane apposition and fusion (Root et al., 2001). Because this pocket is essential for viral infectivity and highly conserved across diverse HIV-1 strains, it is a primary target for the development of fusion inhibitors. Drugs targeting this site, such as the peptide-based inhibitor Albuvirtide or experimental agents like T-1249, bind to the NHR coiled-coil and prevent the transition to the fusion-active state (Liu et al., 2007). This mechanism effectively halts the entry of HIV-1 into host CD4+ T cells, providing a therapeutic option for patients with multi-drug resistant infections.
Inhibition of viral-cell membrane fusion by binding to the N-terminal heptad repeat (NHR) region of gp41, thereby preventing the formation of the six-helix bundle (6HB) required for entry.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human immunodeficiency virus type 1 glycoprotein 41 N-terminal heptad repeat hydrophobic pocket (HIV-1 gp41 NHR hydrophobic pocket).